Crucell N.V. has established two business units for vaccines and proteins in an effort to enhance its focus on specific opportunities for both product units. Mr. Björn Sjöstrand has been appointed to head the Vaccines Business Unit and Mr. Arthur Lahr has been appointed to head the Protein Business Unit.

Mr. Sjöstrand was chief executive officer of SBL Vaccines, which was acquired by Crucell in November 2006. Mr. Lahr was Crucell’s chief strategy officer and executive vice president sales and business development. Both Mr. Sjöstrand and Mr. Lahr will remain members of Crucell’s management committee.

The company has made additional appointments to support its growth strategy. Ms. Oya Yavuz has been named director of investor relations. Ms. Yavuz was previously vice president for investor relations at Wolters Kluwer N.V.

Dr. Herbert Heyneker joined the company’s Protein Business Unit as senior vice president R&D. Dr. Heyneker was formerly chief technical officer of Eos Biotechnology, a functional genomics company he co-founded in 1996. He was involved in founding several life science companies including ProtoGene, GlycoGen and GenPharm International. From 1984 till 1990, he served as vice president, research at Genencor International, and in the early 90s he was a visiting scholar in the Department of Genetics at Stanford University’s Medical School.

The company also announced that chief business officer Kuno Sommer will leave the company in September 2007.

Dr. Ronald H.P. Brus, Crucell’s chief executive officer, remarked, “Crucell has become a global player in the vaccine industry and has established a significant technology presence in the $40 billion protein drug industry. We have now set up dedicated business units with strong leadership to tailor our approach to grow aggressively in these two different but complimentary markets. Additionally, increased transparency in financial results will allow shareholders to follow and value our progress more accurately.”